Format

Send to:

Choose Destination
See comment in PubMed Commons below
Klin Monbl Augenheilkd. 2013 Feb;230(2):127-32. doi: 10.1055/s-0032-1327946. Epub 2013 Jan 20.

[Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].

[Article in German]

Author information

  • 1Augenklinik, Ludwig-Maximilians-Universität, Mathildenstrasse 8, Munich. alice.yu@med.uni-muenchen.de

Abstract

Prostaglandin and prostamide analogues belong to a new substance group which came into the market in the 1990s. They have revolutionised antiglaucomatous therapy by their once-daily dosing regimen and fewer side effects. Today, prostaglandin and prostamide analogues are approved as first-line therapy for patients with primary open-angle glaucoma and ocular hypertension. They lower the intraocular pressure primarily by increasing the uveoscleral outflow. Recent investigations have shown that they also improve the trabecular outflow facility and thus the conventional outflow pathways. Prostaglandin and prostamide analogues are highly efficient in lowering the intraocular pressure, for which they are superior to other antiglaucomatous substance groups. In particular, they appear to have a good control of 24-hour intraocular pressure fluctuations by primarily improving the outflow pathways. Furthermore, they have less systemic side effects than β-blockers. However, their use is often associated with higher costs. In case of undesirable events, they mostly present with ocular symptoms. Based on their good clinical profile, prostaglandin and prostamide analogues play an important role in the primary and additive therapy for glaucoma.

Georg Thieme Verlag KG Stuttgart · New York.

PMID:
23335086
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk